Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: A tool for comparing the efficacy of different treatment strategies and predicting outcome

Blood

Volumn 99, Issue 5, 2002, Pages 1853-1856

  San Miguel, Jesus F S ^{a,b,c,d,e,f,g,h,i}   Almeida, Julia ^{a,b,c,d,e,f,g,h,i}   Mateo, Gema ^{a,b,c,d,e,f,g,h,i}   Bladé, Joan ^{a,b,c,d,e,f,g,h,i}   López Berges, Consuelo ^{a,b,c,d,e,f,g,h,i}   Caballero, Dolores ^{a,b,c,d,e,f,g,h,i}   Hernández, José ^{a,b,c,d,e,f,g,h,i}   Moro, Maria Jesús ^{a,b,c,d,e,f,g,h,i}   Fernández Calvo, Javier ^{a,b,c,d,e,f,g,h,i}   Díaz Mediavilla, Joaquin ^{a,b,c,d,e,f,g,h,i}   Palomera, Luis ^{a,b,c,d,e,f,g,h,i}   Orfao, Alberto ^{a,b,c,d,e,f,g,h,i}  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL GENERAL DE SEGOVIA   (Spain)

^f Hospital Virgen Bianca   (Mexico)

^g HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^h HOSPITAL CLÍNICO SAN CARLOS   (Spain)

ⁱ HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; INTERFERON; MELPHALAN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SURVIVAL TIME;

EID: 0036493775     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.5.1853     Document Type: Article

References (14)

1. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients: Implications for the differential diagnosis between MGUS and multiple myeloma
2. Circulating plasma cells in multiple myeloma: Characterization and correlation with disease stage
3. Phenotypic difference of normal plasma cells from mature myeloma cells
4. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma
5. Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells
6. B7-2-positive myeloma: Incidence, clinical characteristics, prognostic significance, and implications for tumor immunotherapy
7. Mature myeloma cells are proliferative with self-renewal potential
8. Primary plasma cells growing in SCDI-hu mice: A model for studying the biology and treatment of myeloma and its manifestations
9. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: A randomized multicentric study of 487 patients
10. Residual disease detection of leukemia
11. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma
12. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
13. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study
14. High-dose therapy and innovative approaches to treatment of MM